A confirmatory study of APTA-2217 in adult patients with broncial asthma (a placebo-controlled double-blind comparative study).

Trial Profile

A confirmatory study of APTA-2217 in adult patients with broncial asthma (a placebo-controlled double-blind comparative study).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors AstraZeneca; Takeda
  • Most Recent Events

    • 04 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov (Parent trial: NCT00242307).
    • 17 Dec 2008 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 14 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top